Zkusit zdarma
Nuvalent, Inc.

Nuvalent, Inc.

NUVL
Cena:
$ 102.12
+0.88 (0.87%)
Valuace
70
Růst
0
Zdraví
100
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

17:23 21-05-2026

Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive N...

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results

6:30 07-05-2026

NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in ...

Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal

Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal

14:22 30-04-2026

Nuvalent is positioned as a high-quality late-stage biotech with two near-commercial precision oncol...

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

8:05 30-04-2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology...

Evergreen Capital Management LLC Purchases New Position in Nuvalent, Inc. $NUVL

Evergreen Capital Management LLC Purchases New Position in Nuvalent, Inc. $NUVL

4:03 25-04-2026

Evergreen Capital Management LLC purchased a new stake in shares of Nuvalent, Inc. (NASDAQ: NUVL) du...

Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting

Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting

10:32 21-04-2026

Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors out...

New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026

New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026

16:01 17-04-2026

Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NS...

Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC

Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC

6:30 07-04-2026

New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase ...

Alexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) Stock

Alexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) Stock

4:50 05-04-2026

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 11,430 shares of Nuvalent ...

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026

17:15 17-03-2026

CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage bio...

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of “Moderate Buy” by Analysts

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of “Moderate Buy” by Analysts

2:24 17-03-2026

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) has earned an average recommendation of "Moderate Bu...

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

20:00 16-03-2026

Vestal Point Capital sold 1,054,000 Nuvalent shares in the fourth quarter, an estimated $103.93 mill...

Nuvalent, Inc. $NUVL Shares Sold by ArrowMark Colorado Holdings LLC

Nuvalent, Inc. $NUVL Shares Sold by ArrowMark Colorado Holdings LLC

4:26 15-03-2026

ArrowMark Colorado Holdings LLC cut its stake in Nuvalent, Inc. (NASDAQ: NUVL) by 2.0% in the undefi...

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

10:01 23-02-2026

Commodore Capital reduced its Nuvalent stake by 850,000 shares in the fourth quarter; the estimated ...

Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans

Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans

1:02 16-02-2026

Nuvalent (NASDAQ: NUVL) executives highlighted ongoing regulatory milestones for the company's lead ...

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

6:30 05-02-2026

CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage bioph...

Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

2:23 26-01-2026

Shares of Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) have earned an average rating of "Moderate...

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

15:26 13-01-2026

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript...

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

6:30 12-01-2026

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-...

Nuvalent (NASDAQ:NUVL) CFO Sells $412,247.52 in Stock

Nuvalent (NASDAQ:NUVL) CFO Sells $412,247.52 in Stock

6:26 10-01-2026

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 4,236 shares of Nuvalent s...

close

NUVALENT TO PARTICIPATE IN THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026

05-02-2026
CAMBRIDGE, MASS., FEB. 5, 2026 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPH...
Více zde

NUVALENT ANNOUNCES ONTARGET 2026 OPERATING PLAN PROGRESS AND OUTLINES KEY ANTICIPATED 2026 MILESTONES

12-01-2026
FDA ACCEPTED NDA FOR ZIDESAMTINIB FOR THE TREATMENT OF TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-...
Více zde

NUVALENT TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

22-12-2025
CAMBRIDGE, MASS. , DEC. 22, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT'S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION

16-12-2025
NEW YORK, DEC. 16, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT I...
Více zde

NUVALENT APPOINTS RON SQUARER TO BOARD OF DIRECTORS

10-12-2025
CAMBRIDGE, MASS. , DEC. 10, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BI...
Více zde

NUVALENT TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

26-11-2025
CAMBRIDGE, MASS. , NOV. 26, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BI...
Více zde

NUVALENT ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES FROM SELLING STOCKHOLDERS

24-11-2025
CAMBRIDGE, MASS. , NOV. 24, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIO...
Více zde

NUVALENT ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ZIDESAMTINIB FOR THE TREATMENT OF TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC

19-11-2025
NDA BASED ON DATA FROM GLOBAL ARROS-1 PHASE 1/2 CLINICAL TRIAL FDA ASSIGNS PDUFA TARGET ACTION DATE ...
Více zde

NUVALENT ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

18-11-2025
CAMBRIDGE, MASS. , NOV. 18, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIO...
Více zde

NUVALENT ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

17-11-2025
CAMBRIDGE, MASS. , NOV. 17, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BI...
Více zde

NUVALENT ANNOUNCES POSITIVE TOPLINE PIVOTAL DATA FROM ALKOVE-1 CLINICAL TRIAL OF NELADALKIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC

17-11-2025
IN 253 ALK TKI PRE-TREATED PATIENTS, ORR BY BICR WAS 31% (95% CI: 26, 37), WITH INITIAL ESTIMATED DU...
Více zde

NUVALENT ANNOUNCES TIMING OF TOPLINE PIVOTAL DATA FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC FROM ALKOVE-1 CLINICAL TRIAL OF NELADALKIB

14-11-2025
COMPANY TO HOST WEBCAST AND CONFERENCE CALL ON NOVEMBER 17, 2025 AT 8:00AM ET CAMBRIDGE, MASS. , NOV...
Více zde

NUVALENT TO PRESENT PATIENT-REPORTED OUTCOMES DATA FROM ARROS-1 TRIAL OF ROS1-SELECTIVE INHIBITOR, ZIDESAMTINIB, AT 2025 IASLC ASCO NORTH AMERICA CONFERENCE ON LUNG CANCER

04-11-2025
ENCORE PIVOTAL EFFICACY AND SAFETY DATA FROM THE ARROS-1 TRIAL ALSO TO BE PRESENTED DURING POSTER SE...
Více zde

NUVALENT HIGHLIGHTS RECENT PIPELINE PROGRESS, REITERATES KEY ANTICIPATED MILESTONES, AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

30-10-2025
COMPLETED ROLLING NDA SUBMISSION FOR ZIDESAMTINIB IN TKI PRE-TREATED ADVANCED ROS1-POSITIVE NSCLC ON...
Více zde

NUVALENT PRESENTS PRELIMINARY DATA FOR NELADALKIB IN ADVANCED ALK-POSITIVE SOLID TUMORS BEYOND NSCLC AT ESMO 2025

18-10-2025
ENCOURAGING PRELIMINARY ACTIVITY OBSERVED ACROSS DIVERSE SET OF ADVANCED ALK-POSITIVE SOLID TUMORS G...
Více zde

NUVALENT TO PRESENT NEW PRECLINICAL DATA FOR HER2-SELECTIVE INHIBITOR, NVL-330, AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

13-10-2025
CAMBRIDGE, MASS. , OCT. 13, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

NUVALENT TO PARTICIPATE IN THE UBS 2025 VIRTUAL ONCOLOGY DAY

24-09-2025
CAMBRIDGE, MASS. , SEPT. 24, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

NUVALENT PRESENTS PIVOTAL DATA FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC AT WCLC 2025

07-09-2025
ROLLING NDA SUBMISSION FOR ZIDESAMTINIB IN TKI PRE-TREATED ADVANCED ROS1-POSITIVE NSCLC INITIATED UN...
Více zde

NUVALENT TO PARTICIPATE IN THE CANTOR GLOBAL HEALTHCARE CONFERENCE 2025

28-08-2025
CAMBRIDGE, MASS. , AUG. 28, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

NUVALENT TO PRESENT PIVOTAL DATA FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC AT WCLC 2025 PRESIDENTIAL SYMPOSIUM

13-08-2025
CAMBRIDGE, MASS. , AUG. 13, 2025 /PRNEWSWIRE/ --  NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

NUVALENT HIGHLIGHTS PIPELINE AND BUSINESS ACHIEVEMENTS, REITERATES KEY ANTICIPATED MILESTONES, AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

07-08-2025
INITIATED ROLLING NDA SUBMISSION FOR ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-PO...
Více zde

NUVALENT ANNOUNCES INITIATION OF ALKAZAR PHASE 3 RANDOMIZED, CONTROLLED TRIAL EVALUATING NELADALKIB FOR PATIENTS WITH TKI-NAÏVE ALK-POSITIVE NSCLC

21-07-2025
CAMBRIDGE, MASS. , JULY 21, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIO...
Více zde

NUVALENT ANNOUNCES POSITIVE PIVOTAL DATA FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC

24-06-2025
ALIGNED WITH FDA ON NDA SUBMISSION STRATEGY FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIV...
Více zde

NUVALENT ANNOUNCES TIMING OF PIVOTAL DATA FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB

23-06-2025
COMPANY TO HOST WEBCAST AND CONFERENCE CALL ON JUNE 24, 2025 AT 8:00AM ET CAMBRIDGE, MASS. , JUNE 23...
Více zde

NUVALENT APPOINTS CHRISTY OLIGER TO BOARD OF DIRECTORS

18-06-2025
CAMBRIDGE, MASS. , JUNE 18, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

NUVALENT OUTLINES RECENT PIPELINE AND BUSINESS PROGRESS, REITERATES KEY ANTICIPATED MILESTONES, AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

08-05-2025
TOPLINE PIVOTAL DATA EXPECTED FOR ZIDESAMTINIB IN TKI PRE-TREATED ROS1-POSITIVE NSCLC POPULATION IN ...
Více zde

NUVALENT ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS REINFORCING RATIONAL MOLECULAR DESIGN OF ZIDESAMTINIB AS A NOVEL ROS1-SELECTIVE INHIBITOR

29-04-2025
CAMBRIDGE, MASS. , APRIL 29, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BI...
Více zde

NUVALENT TO PRESENT TRIAL IN PROGRESS POSTERS FOR THE ALKAZAR TRIAL OF NELADALKIB AND HEROEX-1 TRIAL OF NVL-330 AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

23-04-2025
CAMBRIDGE, MASS. , APRIL 23, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BI...
Více zde

NUVALENT TO PARTICIPATE IN THE STIFEL 2025 VIRTUAL TARGETED ONCOLOGY FORUM

01-04-2025
CAMBRIDGE, MASS. , APRIL 1, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIO...
Více zde

NUVALENT TO PRESENT NEW PRECLINICAL DATA ON ALK-SELECTIVE INHIBITOR, NELADALKIB, AND ROS1-SELECTIVE INHIBITOR, ZIDESAMTINIB, AT AACR ANNUAL MEETING 2025

25-03-2025
CAMBRIDGE, MASS. , MARCH 25, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE B...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-14 00:00:008-KStáhnout
2025-12-16 00:00:008-KStáhnout
2025-12-10 00:00:008-KStáhnout
2025-11-20 00:00:008-KStáhnout
2025-11-17 00:00:008-KStáhnout
2025-10-30 00:00:008-KStáhnout
2025-10-30 00:00:0010-QStáhnout
2025-09-22 01:00:008-KStáhnout
2025-09-22 00:00:008-KStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-07-21 01:00:008-KStáhnout
2025-07-21 00:00:008-KStáhnout
2025-06-24 01:00:008-KStáhnout
2025-06-24 00:00:008-KStáhnout
2025-06-20 01:00:008-KStáhnout
2025-06-20 00:00:008-KStáhnout
2025-06-10 01:00:008-KStáhnout
2025-06-10 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-04-17 01:00:008-KStáhnout
2025-04-17 00:00:008-KStáhnout
2025-02-27 00:00:008-KStáhnout
2025-02-27 00:00:0010-KStáhnout
2025-02-26 23:00:008-KStáhnout
2025-02-26 23:00:0010-KStáhnout
2025-01-14 00:00:008-KStáhnout
2025-01-13 23:00:008-KStáhnout
2024-12-09 00:00:008-KStáhnout
2024-12-08 23:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-09-17 01:00:008-KStáhnout
2024-09-17 00:00:008-KStáhnout
2024-09-16 01:00:008-KStáhnout
2024-09-16 00:00:008-KStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 01:00:0010-QStáhnout
2024-08-08 00:00:008-KStáhnout
2024-08-08 00:00:0010-QStáhnout
2024-07-22 01:00:008-KStáhnout
2024-07-22 00:00:008-KStáhnout
2024-06-14 01:00:008-KStáhnout
2024-06-14 00:00:008-KStáhnout
2024-05-16 01:00:008-KStáhnout
2024-05-16 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-01-09 00:00:008-KStáhnout
2024-01-08 23:00:008-KStáhnout
2023-11-14 00:00:008-KStáhnout
2023-11-14 00:00:0010-QStáhnout
2023-11-13 23:00:008-KStáhnout
2023-11-13 23:00:0010-QStáhnout
2023-10-17 01:00:008-KStáhnout
2023-10-17 00:00:008-KStáhnout
2023-10-13 01:00:008-KStáhnout
2023-10-13 00:00:008-KStáhnout
2023-10-04 01:00:008-KStáhnout
2023-10-04 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-06-16 01:00:008-KStáhnout
2023-06-16 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-03-16 00:00:008-KStáhnout
2023-03-16 00:00:0010-KStáhnout
2023-03-15 23:00:008-KStáhnout
2023-03-15 23:00:0010-KStáhnout
2023-03-13 00:00:008-KStáhnout
2023-03-12 23:00:008-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-10 00:00:0010-QStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-09 23:00:0010-QStáhnout
2022-11-01 00:00:008-KStáhnout
2022-10-31 23:00:008-KStáhnout
2022-10-28 01:00:008-KStáhnout
2022-10-28 00:00:008-KStáhnout
2022-10-06 01:00:008-KStáhnout
2022-10-06 00:00:008-KStáhnout
2022-08-10 01:00:008-KStáhnout
2022-08-10 01:00:0010-QStáhnout
2022-08-10 00:00:008-KStáhnout
2022-08-10 00:00:0010-QStáhnout
2022-06-21 01:00:008-KStáhnout
2022-06-21 00:00:008-KStáhnout
2022-05-12 01:00:008-KStáhnout
2022-05-12 01:00:0010-QStáhnout
2022-05-12 00:00:008-KStáhnout
2022-05-12 00:00:0010-QStáhnout
2022-03-31 01:00:008-KStáhnout
2022-03-31 00:00:008-KStáhnout
2022-03-29 01:00:008-KStáhnout
2022-03-29 01:00:0010-KStáhnout
2022-03-29 00:00:008-KStáhnout
2022-03-29 00:00:0010-KStáhnout
2022-02-03 00:00:008-KStáhnout
2022-02-02 23:00:008-KStáhnout
2022-01-07 00:00:008-KStáhnout
2022-01-06 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-09-08 01:00:008-KStáhnout
2021-09-08 01:00:0010-QStáhnout
2021-09-08 00:00:008-KStáhnout
2021-09-08 00:00:0010-QStáhnout
2021-08-02 01:00:008-KStáhnout
2021-08-02 00:00:008-KStáhnout
preloader